Arca
Skip to content
Tools
Tools

KCNJ8: ATP-sensitive inward rectifier potassium channel 8

Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on KCNJ8, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Diazoxide

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        DiazoxideApprovedMerck & Co. (MSD)Small moleculeOpenerPotassium channel, inwardly rectifying, subfamily J, member 8 opener5

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.
        Diazoxide in the Treatment of Type 1 GlycogenosisDiazoxide—Not yet recruitingCentral Hospital, Nancy, FranceJul 31, 2026
        Observational Study of VYKAT™ XR in Patients With Prader-Willi SyndromeDiazoxide—Enrolling by invitationSoleno Therapeutics, Inc.Mar 5, 2026
        Effect of Insulin Lowering on LipogenesisDiazoxidePhase 1RecruitingColumbia UniversityFeb 11, 2026
        Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Diazoxide—RecruitingDuke UniversityFeb 20, 2020
        Regulation of Endogenous Glucose Production by Central KATP ChannelsDiazoxidePhase 2RecruitingAlbert Einstein College of MedicineMay 30, 2018

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Hypertrichotic osteochondrodysplasia Cantu type0.63
        • Sudden infant death syndrome0.58
        • Hypertensive disorder0.47
        • Hyperinsulinism0.44
        • Hyperinsulinemic hypoglycemia0.37
        • Pancreatic insulinoma0.37
        • Obesity disorder0.29
        • Cardiac arrhythmia0.21
        • Brugada syndrome0.21
        • Abnormality of the cardiovascular system0.19
        • Congenital isolated hyperinsulinism0.18

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4770, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q15842, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.